125 related articles for article (PubMed ID: 2097149)
1. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.
de Oliveira CF; Lacave AJ; Villani C; Wolff JP; di Re F; Namer M; Maskens A; George M; Dalesio O; Rotmensz N
Eur J Gynaecol Oncol; 1990; 11(5):323-30. PubMed ID: 2097149
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
4. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
5. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
6. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
Krommer CF; Szalai JP
Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
[TBL] [Abstract][Full Text] [Related]
10. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
11. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
Hernádi Z; Juhász B; Póka R; Lampé LG
Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
14. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
[TBL] [Abstract][Full Text] [Related]
17. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
[TBL] [Abstract][Full Text] [Related]
18. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
[TBL] [Abstract][Full Text] [Related]
20. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
